| 摘要: |
| ［摘要］ 目的 研究非肥胖2型糖尿病患者血清内脂素(visfatin)与尿微量白蛋白/肌酐（ACR）之间的相关性，探讨内脂素在不同阶段糖尿病肾病中的改变。方法 收集体重指数（BMI）<28 kg/m2的2型糖尿病患者90例，按照尿ACR分为单纯糖尿病组30例（T2DM组，尿ACR<30 μg/mg），微量蛋白尿组30例（DN1组，尿ACR30～300 μg/mg），大量蛋白尿组30例(DN2组，尿ACR>300 μg/mg)，健康体检人员组（对照组）30例，测定血清内脂素及血脂、血糖等生化指标。结果 非肥胖2型糖尿病患者组血清内脂素水平显著高于对照组（P<0.01），糖尿病肾病患者组血清内脂素水平显著高于单纯糖尿病组（P<0.01），其中大量蛋白尿组血清内脂素水平显著高于微量蛋白尿组（P<0.01）。血清内脂素与尿ACR水平呈正相关（r=0.558,P<0.01）。结论 非肥胖的2型糖尿病患者血清内脂素水平升高，与尿ACR密切相关，随着糖尿病肾病加重，内脂素也逐渐升高。内脂素有希望作为糖尿病肾病的治疗靶点。 |
| 关键词: 内脂素 糖尿病肾病 2型糖尿病 非肥胖 |
| DOI：10.3969/j.issn.1674-3806.2018.06.03 |
| 分类号:R 58 |
| 基金项目:广西卫计委科研课题（编号：Z2012231） |
|
| Relationship between serum visfatin and diabetic nephropathy in non-obese patients with type 2 diabetes |
|
LU Xin-hong, WEN Yu-jie, HU Xin, et al.
|
|
Department of Endocrinology, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin 541002, China
|
| Abstract: |
| ［Abstract］ Objective To explore the relationship between serum visfatin level and urine albumin-to-creatinine ratio(ACR) in non-obese patients with type 2 diabetes, and to investigate the changes of visfatin in diabetic nephropathy at different stages. Methods 90 patients with type 2 diabetes and body mass index(BMI)<28 kg/m2 were divided into 3 groups according to the different urine ACRs: T2DM group(urine ACR<30 μg/mg), DN1 group(urine ACR 30～300 μg/mg) and DN2 group（urine ACR>300 μg/mg). 30 healthy volunteers were collected as the control group. The levels of serum visfatin, glucose and blood lipid, and renal function were compared among the groups. Results The level of serum visfatin in non-obese patients with type 2 diabetes was significantly higher than that in the control group(P<0.01). The level of serum visfatin in diabetic nephropathy patients was significantly higher than that in simple diabetic patients(P<0.01), and visfatin level in patients with massive albuminuria was higher than that in the patients with microalbuminuria(P<0.01). Serum visfatin and urine ACR levels were positively correlated(r=0.558, P<0.01). Conclusion The level of serum visfatin is elevated in non-obese patients with type 2 diabetes, and closely related to urine ACR. With the aggravation of diabetic nephropathy, visfatin is gradually increased. Visfatin has the potential to be therapeutic targets for diabetic nephropathy. |
| Key words: Visfatin Diabetic nephropathy Type 2 diabetes Non-obese |
